Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Neumann

Showing results (41-50 of 301) with videos related to

Pageof 31
Sort By:
The New England Journal of Medicine|November 19, 2015
Measuring the Value of Prescription DrugsPeter J Neumann, Joshua T Cohen
Diabetes Care|July 30, 2008
Reducing cardiovascular disease: opportunities and consequencesPeter J Neumann, Joshua T Cohen
Health Affairs (Project Hope)|September 11, 2008
Using decision analysis to better evaluate pediatric clinical guidelinesJoshua T Cohen, Peter J Neumann
Health Services Research|August 19, 2009
A framework to measure the value of public health servicesPeter D Jacobson, Peter J Neumann
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 28, 2007
Dialysis facility ownership and epoetin dosing in hemodialysis patients: a medical economic perspectiveJoshua T Cohen, Peter J Neumann
JAMA|April 18, 2023
Cost-effectiveness Thresholds Used by Study Authors, 1990-2021Peter J Neumann, David D Kim
The New England Journal of Medicine|November 2, 2012
Medicare's enduring struggle to define "reasonable and necessary" carePeter J Neumann, James D Chambers
Mabs|March 2, 2012
The cost-effectiveness of biopharmaceuticals: a look at the evidenceAndrew W Wilson, Peter J Neumann
Expert Review of Pharmacoeconomics & Outcomes Research|June 16, 2010
US healthcare reform: implications for health economics and outcomes researchJames D Chambers, Peter J Neumann
Pharmacoeconomics|August 10, 2017
ICER's Revised Value Assessment Framework for 2017-2019: A CritiquePeter J Neumann, Joshua T Cohen
Pageof 31

Showing results (41-50 of 301) with videos related to

Sort By:
Pageof 31
The New England Journal of Medicine|November 19, 2015
Measuring the Value of Prescription DrugsPeter J Neumann, Joshua T Cohen
Diabetes Care|July 30, 2008
Reducing cardiovascular disease: opportunities and consequencesPeter J Neumann, Joshua T Cohen
Health Affairs (Project Hope)|September 11, 2008
Using decision analysis to better evaluate pediatric clinical guidelinesJoshua T Cohen, Peter J Neumann
Health Services Research|August 19, 2009
A framework to measure the value of public health servicesPeter D Jacobson, Peter J Neumann
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 28, 2007
Dialysis facility ownership and epoetin dosing in hemodialysis patients: a medical economic perspectiveJoshua T Cohen, Peter J Neumann
JAMA|April 18, 2023
Cost-effectiveness Thresholds Used by Study Authors, 1990-2021Peter J Neumann, David D Kim
The New England Journal of Medicine|November 2, 2012
Medicare's enduring struggle to define "reasonable and necessary" carePeter J Neumann, James D Chambers
Mabs|March 2, 2012
The cost-effectiveness of biopharmaceuticals: a look at the evidenceAndrew W Wilson, Peter J Neumann
Expert Review of Pharmacoeconomics & Outcomes Research|June 16, 2010
US healthcare reform: implications for health economics and outcomes researchJames D Chambers, Peter J Neumann
Pharmacoeconomics|August 10, 2017
ICER's Revised Value Assessment Framework for 2017-2019: A CritiquePeter J Neumann, Joshua T Cohen
Pageof 31